Withdrawn trial aimed to stop bodies from fighting rare disease drug
NCT ID NCT05494593
Summary
This study aimed to see if a combination of immune-suppressing drugs could help young boys with Hunter syndrome better tolerate their main enzyme replacement therapy (ELAPRASE). The goal was to prevent their immune systems from developing antibodies that could block the treatment's effectiveness. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTER SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, Illinois, 60611, United States
-
Children's Hospital and Research Center at Oakland
Oakland, California, 94609, United States
-
Children's Hospitals and Clinics of Minnesota
Minneapolis, Minnesota, 55404, United States
-
NewYork-Presbyterian Morgan Stanley Children's Hospital
New York, New York, 10032, United States
-
Phoenix Childrens Hospital
Phoenix, Arizona, 85016, United States
-
Rady Childrens Hospital San Diego - PIN
San Diego, California, 92123, United States
-
The Cleveland Clinic Foundation
Twinsburg, Ohio, 44087, United States
-
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center
Torrance, California, 90502, United States
Conditions
Explore the condition pages connected to this study.